ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1412

Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study

Meltem Alkan Melikoglu1 and Kazim Senel2, 1Rheumatology, Ataturk University Faculty of Medicine, Erzurum, Turkey, 2Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disability, rheumatoid arthritis (RA) and sarcopenia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is associated with increased morbidity and mortality due to several metabolic deteriorations one of which is sarcopenia. The aim of this cross-sectional pilot study was to investigate sarcopenia in patients with RA and to evaluate its relation to the disability assessment.

Methods: Forty female patients with RA and age-gender and body mass index (BMI) matched 40 healthy controls were included. Demographic data, pain, morning stiffness duration, disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and the Health Assessment Questionnaire (HAQ) were evaluated. Body compositions were assessed with whole body dual energy X-ray absorptiometry. We compared the appendicular appendicular skeletal muscle mass (ASM) and skeletal muscle mass index (SMI) of patients to their healthy matches. Also possible correlations between SMI and the disease characteristics and HAQ score were investigated. The independent samples t test and the Pearson’s correlation test were used to evaluate the data.  

Results:

The mean age of the patients and controls were 48,29 ±8,34 and 46.21±6.90 years, respectively. The BMI values, percentages of obese, overweigth and healthy weight subjects were similar in patient and control groups. However, ASM and SMI calculations were found to be significantly lower in patients with RA than those in controls (p<0,05). The percentage of sarcopenia was significantly higher in patients with RA than that in their age-gender and BMI similar healthy matches (20% and 7%; respectively; p<0,05). Although there were no significant correlation between SMI and age, disease duration, morning stiffness, pain, DAS28 levels and laboratory investigations, a significant negative correlation was determined between SMI and HAQ score in patients with RA (p<0,05).

Conclusion:

We demontrated lower SMI values and higher sarcopenia ratios in patients with RA than their age-gender and BMI similar healthy matches. Also, independetly from other disease characteristics, the inverse correlation between SMI and HAQ scores found in our study may contribute the understanding of the impact of the process on the disability of the patients.


Disclosure:

M. A. Melikoglu,
None;

K. Senel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sarcopenia-and-its-impact-on-disability-in-rheumatoid-arthritis-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology